Jupiter Topco LLC Invests $88.80 Million in Olema Pharmaceuticals, Inc. $OLMA

Jupiter Topco LLC acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,094,413 shares of the company’s stock, valued at approximately $88,803,000. Jupiter Topco LLC owned 0.08% of Olema Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Siren L.L.C. lifted its position in Olema Pharmaceuticals by 44.1% during the 1st quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock worth $70,926,000 after buying an additional 1,456,249 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $24,100,000. Defilade Capital Management L.P. lifted its holdings in Olema Pharmaceuticals by 21.9% during the 1st quarter. Defilade Capital Management L.P. now owns 1,504,536 shares of the company’s stock valued at $22,433,000 after purchasing an additional 269,902 shares during the last quarter. SEB Asset Management AB bought a new stake in shares of Olema Pharmaceuticals during the 1st quarter worth about $5,061,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Olema Pharmaceuticals by 12.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,082,434 shares of the company’s stock worth $16,134,000 after acquiring an additional 123,790 shares during the period. 91.78% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of Olema Pharmaceuticals stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the sale, the director directly owned 715,270 shares of the company’s stock, valued at approximately $8,282,826.60. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OLMA. JPMorgan Chase & Co. reduced their target price on shares of Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating for the company in a research report on Thursday, August 13th. Weiss Ratings raised shares of Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Citigroup dropped their price objective on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. HC Wainwright cut their target price on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Finally, Guggenheim cut their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Olema Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $42.40.

Olema Pharmaceuticals Stock Down 0.5%

Shares of Olema Pharmaceuticals stock opened at $10.85 on Thursday. The firm has a market cap of $949.38 million, a price-to-earnings ratio of -5.12 and a beta of 2.03. Olema Pharmaceuticals, Inc. has a one year low of $5.36 and a one year high of $36.26. The stock’s 50-day moving average is $11.41 and its 200 day moving average is $14.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.86 and a quick ratio of 8.86.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). Equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.43 EPS for the current year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.